EUCTR2013-001280-23-HU进行中（未招募）1 期
An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose with Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity during Treatment of Osteosarcoma Patients - Investigation of Modufolin® as rescue therapy for osteosarcoma patients treated with HDMTX
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients must have histological evidence of osteosarcoma including metastatic osteosarcoma.
- •2.Patients must be eligible for high-dose methotrexate treatment (HDMTX) according to the MAP treatment schedule described in the study protocol (see Appendix 1) and fulfill all of the criteria below prior to first course of HDMTX in the study.
- •a.Serum MTX: = 0.1µmol/L
- •b.Neutrophils: = 0.25 x 109/L
- •c.Platelets: = 50 x 109/L
- •d.Serum bilirubin: = 1.25 x ULN
- •e.GFR = 70 mL/min/1.73 m2
- •f.No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential HDMTX administration, at the discretion of the investigator.
- •3.Patients must be enrolled in HDMTX course 1, 3 or 5 of the MAP treatment schedule (see Appendix 1).
- •4.Patients enrolled in HDMTX course 3 or 5 must have a history of successful advancement from first to second HDMTX course within the previous MAP cycle, i.e. fulfilling all of the following criteria 8 days after start of first HDMTX course within the same MAP cycle:
- •a.Serum MTX: = 0.1µmol/L
- •b.Neutrophils: = 0.25 x 109/L
- •c.Platelets: = 50 x 109/L
- •d.Serum bilirubin: = 1.25 x ULN
- •e.GFR = 70 mL/min/1.73 m2
- •f.No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential HDMTX administration, at the discretion of the investigator.
- •5.Patients enrolled in HDMTX course 3 or 5 must have a history of successful advancement to next MAP cycle after end of previous MAP cycle, i.e. fulfilling all of the following criteria 8 days after start of the second HDMTX course in previous MAP cycle:
- •a.Serum MTX: = 0.1µmol/L
- •b.Neutrophils: = 0.75 x 109/L
- •c.Platelets: = 75 x 109/L
- •d.Serum bilirubin: = 1.25 x ULN
- •e.GFR = 70 mL/min/1.73 m2
- •f.No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential HDMTX administration, at the discretion of the investigator.
- •6.Patients must be 12-40 years of age. The age limit may be lowered to 6-40 years for enrolment in Cohort 2 (only) and if recommended by the DSMB.
- •7.Sexually active females of childbearing potential: Must be surgically sterile, or compliant with a contraceptive regimen during and for six (6) months after last MTX dose in MAP regimen; must have a negative serum or urine pregnancy test (within seven (7) days before study enrolment) and must not be lactating.
- •8.Sexually active males: Must be surgically sterile or compliant with a contraceptive regimen during and for six (6) months after last MTX dose in MAP regimen.
- •9.Patient, parent(s), or guardian(s), as appropriate, is/are willing and able to provide signed informed consent.
- •10.Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.
- •11.Patients who have undergone surgical resection of their tumor must have recovered from their surgery and be eligible to continue on the MAP regimen; any post-operative complications should be resolved to NCI CTCAE v4.0 Grade 1 or better.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 18
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Involvement in another clinical trial within 30 days before enrolment in the study.
- •2.Hypersensitivity to Calcium Folinate.
- •3.Previous treatment with glucarpidase.
- •4.Known serious concomitant systemic disorders (e.g., active infection including HIV, liver dysfunction, cardiac disease) that, in the opinion of the investigator, would compromise the patient's ability to complete the study
研究者
相似试验
进行中（未招募）
1 期
Study to identify an appropriate Modufolin® dose with respect to safety and ability to mitigate high-dose Methotrexate induced toxicity in osteosarcoma patients.EUCTR2013-001280-23-SEIsofol Medical AB18
进行中（未招募）
1 期
Study to identify an appropriate Modufolin® dose with respect to safety and ability to mitigate high-dose Methotrexate induced toxicity in osteosarcoma patients.Rescue after High Dose Methotrexate therapy in Osteosarcoma patients.MedDRA version: 18.1Level: PTClassification code 10061814Term: DetoxificationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-001280-23-CZIsofol Medical AB18
进行中（未招募）
1 期
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients with Solid Tumors (NECVAX-NEO1-02-INT).Advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2024-511212-24-00EC Bio Therapeutics GmbH40
进行中（未招募）
1 期
A Phase II/III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3), Administered for 12 Months in Children and Adolescents with Growth Hormone Insensitivity Syndrome (GHIS) such as Laron Syndrome.Growth Hormone Insensitivity Syndrome (GHIS) is a genetically disturbance of the biological action of growth hormone (GH). This study is intended to evaluate the ability of rhIGF-I/rhIGFBP-3 to demonstrate height velocity increases, in pre-pubertal children with GHIS and to evaluate the safety profile of extended treatment with rhIGF-I/rhIGFBP-3, believed to be more favorable that that observed with rhIGF-I.EUCTR2004-000644-25-SKInsmed Incorporated40
已完成
2 期
An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment, with or without second surgery.GlioblastomaNL-OMON48738VAXIMM GmbH9